SurModics (SRDX) Tops Q4 EPS by 8c, Revenues Beat; FY19 EPS Mid-Point Below Consensus, FY18 Revenue Outlook Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. USO
2. MRVL
3. SPY
4. NVDA
5. BBIO
6. GOOGL
7. OPCH
8. AMD
9. CHRW
10. SKYD

Go back to SurModics (SRDX) Tops Q4 EPS by 8c, Revenues Beat; FY19 EPS Mid-Point Below Consensus, FY18 Revenue Outlook Above Consensus

Surmodics Reports Fourth Quarter Fiscal 2018 Results and Issues Fiscal 2019 Guidance

November 9, 2018 7:30 AM EST

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 fourth quarter ended September 30, 2018, and provided its financial outlook for fiscal 2019.

Summary of Fourth Quarter Fiscal 2018 Highlights and Fiscal 2019 Guidance

Revenue of $23.0 million, an increase of 15% year-over-year GAAP EPS of ($0.13), non-GAAP EPS of $0.05 Submitted application for first in-human study for arteriovenous (AV) access drug coated balloon (DCB) Fiscal... More